The company stated that the approval paves the way for marketing of Enhertu in India for the specified additional indication, subject to receipt of other related statutory approvals, if any. Shares of Astrazeneca Pharma India Ltd ended at ₹9,320.00, up by ₹98.75, or 1.07%, on the BSE.
